Venturi Wealth Management LLC Buys Shares of 1,150 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Venturi Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,150 shares of the biopharmaceutical company’s stock, valued at approximately $96,000.

Several other institutional investors have also recently made changes to their positions in the company. True Wealth Design LLC purchased a new stake in Intra-Cellular Therapies in the third quarter worth about $32,000. GAMMA Investing LLC raised its holdings in shares of Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 240 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of Intra-Cellular Therapies in the 3rd quarter worth approximately $74,000. Wilmington Savings Fund Society FSB bought a new position in shares of Intra-Cellular Therapies during the third quarter valued at approximately $97,000. Finally, Quarry LP increased its holdings in Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 1,300 shares during the period. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ITCI shares. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Royal Bank of Canada restated a “sector perform” rating and set a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. StockNews.com started coverage on Intra-Cellular Therapies in a research note on Monday. They issued a “hold” rating on the stock. Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday. Nine analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $103.62.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock opened at $128.60 on Monday. The business has a fifty day moving average of $110.27 and a 200 day moving average of $89.84. Intra-Cellular Therapies, Inc. has a 1 year low of $62.78 and a 1 year high of $128.77. The firm has a market capitalization of $13.67 billion, a price-to-earnings ratio of -147.81 and a beta of 0.72.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. As a group, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Insider Buying and Selling at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.